Moore Kathleen N, Moxley Katherine M, Fader Amanda Nickles, Axtell Allison E, Rocconi Rodney P, Abaid Lisa N, Cass Ilana A, Rose Peter G, Leath Charles A, Rutledge Teresa, Blankenship Derek, Gold Michael A
University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Blvd, Oklahoma City, OK 73104, USA.
Gynecol Oncol. 2007 Dec;107(3):398-403. doi: 10.1016/j.ygyno.2007.09.027. Epub 2007 Nov 7.
Primary carcinoma of the fallopian tube (PCFT) is a rare malignancy comprising 1% of genital tract cancers. We sought to compare survival trends between PCFT and ovarian carcinoma (OC) patients (pts) in a matched, case-control comparison.
Patients with PCFT were identified from five academic centers. Two OC controls were identified for each PCFT pt based on age, stage, and residual disease. All pts were surgically staged and treated with platinum based chemotherapy (CT) if indicated. PFS and OS were then compared with Kaplan-Meier analysis.
96 PCFT cases and 189 OC controls were identified. 50 early stage PCFT were matched with 97 OC pts. The most common CT regimen was carboplatinum and paclitaxel in 84 and 86% respectively. Median follow-up was 57 and 42 months for the PCFT and OC groups and 5-year overall survival (OS) differed at 95% and 76% (p=0.02). 46 Stage III/IV PCFT pts were matched with 92 OC controls. 88.5% were optimally debulked. Median follow-up was 33 and 35 months for PCFT and OC pts and 3-year overall survival was 59% for both groups.
This is the first study to compare outcomes for PCFT and OC in a matched, case-control comparison. Our study demonstrates that, for advanced stage PCFT, a similar survival outcome is obtained compared to OC patients. This should reassure clinicians that treatment of PCFT should mirror that of OC and that PCFT should be included in clinical trials.
原发性输卵管癌（PCFT）是一种罕见的恶性肿瘤，占生殖道癌症的1%。我们试图在匹配的病例对照比较中比较PCFT和卵巢癌（OC）患者的生存趋势。
从五个学术中心识别出PCFT患者。根据年龄、分期和残留疾病，为每个PCFT患者确定两名OC对照。所有患者均接受手术分期，如有指征则接受铂类化疗（CT）。然后采用Kaplan-Meier分析比较无进展生存期（PFS）和总生存期（OS）。
识别出96例PCFT病例和189例OC对照。50例早期PCFT与97例OC患者匹配。最常见的CT方案分别是卡铂和紫杉醇，分别占84%和86%。PCFT组和OC组的中位随访时间分别为57个月和42个月，5年总生存率分别为95%和76%（p=0.02）。46例III/IV期PCFT患者与92例OC对照匹配。88.5%的患者达到最佳减瘤效果。PCFT和OC患者的中位随访时间分别为33个月和35个月，两组的3年总生存率均为59%。
这是第一项在匹配的病例对照比较中比较PCFT和OC结果的研究。我们的研究表明，对于晚期PCFT，与OC患者相比可获得相似的生存结果。这应使临床医生放心，PCFT的治疗应与OC相似，并且PCFT应纳入临床试验。
